Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy

• Levels of circulating tissue factor (TF) [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  

• Alteration in coagulation parameters [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  
• Correlation of TF with markers of coagulation activation and endothelial activation [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  
• Incidence of venous thromboembolism [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  

Other: enzyme-linked immunosorbent assay
Measurement of markers of coagulation and endothelial activation
Other: laboratory biomarker analysis
The PPP will be used for in vitro assays to measure TF activity, coagulation markers and markers of endothelial cell damage
Other: medical chart review
The patient's clinical course with respect to development of venous thromboembolism and response to treatment will be monitored for a total of 3 months from enrollment.

OBJECTIVES:

Primary

• To measure levels of circulating tissue factor (TF) in patients with newly diagnosed multiple myeloma at several time points before, during, and after the administration of chemotherapy and/or antiangiogenic agents.

Secondary

• To measure the correlation of TF with two markers of coagulation activation (i.e., D-dimer, thrombin-antithrombin [TAT] complexes) and two markers of endothelial activation (i.e., soluble E-selectin, soluble thrombomodulin) in these patients.
• To measure and compare (descriptively) our microparticle-associated TF procoagulant activity assay with two other assays using samples from these patients.

OUTLINE: Patients undergo blood sample collection at baseline and then periodically during treatment. Circulating tissue factor (TF) activity levels and coagulation and endothelial activation (by ELISA) are measured. Medical charts are reviewed for sociodemographic and medical information.

After completion of study, patients are followed up for 3 months.